Systematic Review and Meta-Analysis on the Use of Photon-based Stereotactic Radiosurgery Versus Fractionated Stereotactic Radiotherapy for the Treatment of Uveal Melanoma.
Samuel Kosydar, Jake C Robertson, Michael Woodfin, Nina A Mayr, Arjun Sahgal, Robert D Timmerman, Simon S Lo
{"title":"Systematic Review and Meta-Analysis on the Use of Photon-based Stereotactic Radiosurgery Versus Fractionated Stereotactic Radiotherapy for the Treatment of Uveal Melanoma.","authors":"Samuel Kosydar, Jake C Robertson, Michael Woodfin, Nina A Mayr, Arjun Sahgal, Robert D Timmerman, Simon S Lo","doi":"10.1097/COC.0000000000000775","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this report is to assess the efficacy and adverse event profile of photon-based stereotactic radiosurgery (SRS) compared with fractionated stereotactic radiotherapy (fSRT) for the treatment of uveal melanoma. Primary outcomes include incidence proportions of local control, enucleation, metastatic progression, disease-specific, and overall mortality. Treatment-related toxicities such as incidence proportions of radiation retinopathy, neovascular glaucoma, optic neuropathy, and cataract formation were examined as secondary outcomes. Five-year survival and 5-year local control rates were also assessed.</p><p><strong>Materials and methods: </strong>PubMed, Embase, Web of Science, Scopus, and 2 Cochrane databases were searched up to December 31, 2018. Random effects models were used to calculate pooled incidence proportions of outcome measures. Meta-regression was carried out to explore the potential impact of dose per fraction on local control.</p><p><strong>Results: </strong>Twenty-four articles with a total of 1745 patients were included in the meta-analysis. There were no statistically significant differences between photon-based fSRT and SRS for all primary, secondary and 5-year outcome measures, including local control (P=0.28), enucleation (P=0.51), and neovascular glaucoma (P=0.40). The 5-year local control rate was 90% (95% confidence interval: 76%, 96%) for fSRT and 89% (70%, 97%) for SRS.</p><p><strong>Conclusions: </strong>Our meta-analysis showed no difference in tumor control, survival and toxicities, as defined in this paper, between SRS and fSRT for uveal melanoma. Confounding biases remain an expected limitation in this study of novel treatment modalities deployed in rare tumors. Further investigation is needed to validate outcomes and compare stereotactic treatment techniques.</p>","PeriodicalId":501816,"journal":{"name":"American Journal of Clinical Oncology","volume":" ","pages":"32-42"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000000775","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8
Abstract
Purpose: The purpose of this report is to assess the efficacy and adverse event profile of photon-based stereotactic radiosurgery (SRS) compared with fractionated stereotactic radiotherapy (fSRT) for the treatment of uveal melanoma. Primary outcomes include incidence proportions of local control, enucleation, metastatic progression, disease-specific, and overall mortality. Treatment-related toxicities such as incidence proportions of radiation retinopathy, neovascular glaucoma, optic neuropathy, and cataract formation were examined as secondary outcomes. Five-year survival and 5-year local control rates were also assessed.
Materials and methods: PubMed, Embase, Web of Science, Scopus, and 2 Cochrane databases were searched up to December 31, 2018. Random effects models were used to calculate pooled incidence proportions of outcome measures. Meta-regression was carried out to explore the potential impact of dose per fraction on local control.
Results: Twenty-four articles with a total of 1745 patients were included in the meta-analysis. There were no statistically significant differences between photon-based fSRT and SRS for all primary, secondary and 5-year outcome measures, including local control (P=0.28), enucleation (P=0.51), and neovascular glaucoma (P=0.40). The 5-year local control rate was 90% (95% confidence interval: 76%, 96%) for fSRT and 89% (70%, 97%) for SRS.
Conclusions: Our meta-analysis showed no difference in tumor control, survival and toxicities, as defined in this paper, between SRS and fSRT for uveal melanoma. Confounding biases remain an expected limitation in this study of novel treatment modalities deployed in rare tumors. Further investigation is needed to validate outcomes and compare stereotactic treatment techniques.
目的:本报告的目的是评估基于光子的立体定向放射手术(SRS)与分步立体定向放疗(fSRT)治疗葡萄膜黑色素瘤的疗效和不良事件。主要结局包括局部控制、去核、转移进展、疾病特异性和总死亡率的发生率。治疗相关的毒性,如放射性视网膜病变、新生血管性青光眼、视神经病变和白内障形成的发生率作为次要结果进行检查。5年生存率和5年局部控制率也进行了评估。材料和方法:检索截至2018年12月31日的PubMed、Embase、Web of Science、Scopus和2个Cochrane数据库。随机效应模型用于计算结果测量的合并发生率。采用meta回归方法探讨每组分剂量对局部控制的潜在影响。结果:24篇文章共1745例患者被纳入meta分析。基于光子的fSRT和SRS在所有主要、次要和5年预后指标上均无统计学差异,包括局部对照(P=0.28)、眼球摘除(P=0.51)和新生血管性青光眼(P=0.40)。fSRT的5年局部控制率为90%(95%置信区间:76%,96%),SRS的5年局部控制率为89%(70%,97%)。结论:我们的荟萃分析显示,在葡萄膜黑色素瘤的治疗中,SRS和fSRT在肿瘤控制、生存和毒性方面没有差异。混杂偏倚仍然是预期的限制,在这项研究的新治疗方式部署在罕见的肿瘤。需要进一步的研究来验证结果并比较立体定向治疗技术。